Buys | $2,720,023 | 3 | 75 |
Sells | $76,247 | 1 | 25 |
Samsara BioCapital GP, LLC | 10 percent owner | 1 | $1.26M | 0 | $0 | $1.26M |
McMinn Rachel | Chief Executive Officer | 1 | $969,000 | 0 | $0 | $969,000 |
Cvijic Christine Mikail | President and CFO | 1 | $491,400 | 1 | $76,247 | $415,153 |
Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.
Over the last 12 months, insiders at Neurogene Inc. have bought $2.72M and sold $76,247 worth of Neurogene Inc. stock.
On average, over the past 5 years, insiders at Neurogene Inc. have bought $2.72M and sold $76,247 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Samsara BioCapital GP, LLC (10 percent owner) — $1.26M. McMinn Rachel (Chief Executive Officer) — $969,000. Cvijic Christine Mikail (President and CFO) — $491,400.
The last purchase of 48,770 shares for transaction amount of $1.26M was made by Samsara BioCapital GP, LLC (10 percent owner) on 2024‑11‑26.
2025-03-13 | Sale | Cvijic Christine Mikail | President and CFO | 4,501 0.0216% | $16.94 | $76,247 | -0.89% | |
2024-11-26 | Samsara BioCapital GP, LLC | 10 percent owner | 48,770 0.3334% | $25.83 | $1.26M | -31.22% | ||
2024-11-22 | McMinn Rachel | Chief Executive Officer | 47,500 0.2565% | $20.40 | $969,000 | -8.24% | ||
2024-11-22 | Cvijic Christine Mikail | President and CFO | 24,000 0.1301% | $20.48 | $491,400 | -8.24% |
Increased Positions | 58 | +60.42% | 5M | +37.37% |
Decreased Positions | 42 | -43.75% | 3M | -20.97% |
New Positions | 28 | New | 946,654 | New |
Sold Out Positions | 25 | Sold Out | 2M | Sold Out |
Total Postitions | 112 | +16.67% | 16M | +16.4% |
Samsara Biocapital, Llc | $28,676.00 | 8.18% | 1.72M | +449,337 | +35.44% | 2024-12-31 |
Blackrock, Inc. | $25,320.00 | 7.22% | 1.52M | +144,278 | +10.52% | 2024-12-31 |
Rtw Investments, Lp | $22,549.00 | 6.43% | 1.35M | +215,000 | +18.94% | 2024-12-31 |
Redmile Group, Llc | $22,040.00 | 6.29% | 1.32M | +355,416 | +36.86% | 2024-12-31 |
Casdin Capital, Llc | $21,633.00 | 6.17% | 1.3M | +770,745 | +146.92% | 2024-12-31 |
Ecor1 Capital, Llc | $21,231.00 | 6.05% | 1.27M | 0 | 0% | 2024-12-31 |
Fmr Llc | $14,368.00 | 4.1% | 860,333 | +128,532 | +17.56% | 2024-12-31 |
Commodore Capital Lp | $13,360.00 | 3.81% | 800,000 | +600,000 | +300% | 2024-12-31 |
Baker Bros. Advisors Lp | $11,263.00 | 3.21% | 674,450 | +218,435 | +47.9% | 2024-12-31 |
Vanguard Group Inc | $9,486.00 | 2.71% | 568,016 | -8,144 | -1.41% | 2024-12-31 |